Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ruberti

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 1996
An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitroG Papoff, I Cascino, A Eramo, et al.
Diabetologia|February 3, 1998
CD95 and CD95-ligand expression in endocrine pancreas of NOD, NOR and BALB/c miceA Signore, A Annovazzi, E Procaccini, et al.
Clinical and Experimental Immunology|November 1, 1987
In vitro anti-HBs antibody synthesis from anti-hepatitis B vaccine recipientsV Barnaba, M Levrero, G Ruberti, et al.
Liver|February 1, 1986
Characterization of effector cells in lymphocytotoxicity to autologous hepatocytes in HBsAg-positive and autoimmune chronic active hepatitis (CAH)V Barnaba, M Levrero, A Franco, et al.
The Journal of Biological Chemistry|December 23, 1999
Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptorG Papoff, P Hausler, A Eramo, et al.
The EMBO Journal|December 1, 1995
Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signalM G Cifone, P Roncaioli, R De Maria, et al.
Human Immunology|May 1, 1991
Molecular analysis of the role of the HLA class II genes DRB1, DQA1, DQB1, and DPB1 in susceptibility to Lyme arthritisG Ruberti, A B Begovich, A C Steere, et al.
Cell Death and Differentiation|April 14, 1999
The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosisM Tolomeo, L Dusonchet, M Meli, et al.
Journal of Hepatology|January 1, 1986
Effect of 28 consecutive days lymphoblastoid interferon (alpha-IFN) administration on hepatitis B virus related chronic liver diseaseA Franco, V Barnaba, M Levrero, et al.
The Journal of Experimental Medicine|January 1, 1992
Presentation of antigen by mixed isotype class II molecules in normal H-2d miceG Ruberti, K S Sellins, C M Hill, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 1996
An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitroG Papoff, I Cascino, A Eramo, et al.
Diabetologia|February 3, 1998
CD95 and CD95-ligand expression in endocrine pancreas of NOD, NOR and BALB/c miceA Signore, A Annovazzi, E Procaccini, et al.
Clinical and Experimental Immunology|November 1, 1987
In vitro anti-HBs antibody synthesis from anti-hepatitis B vaccine recipientsV Barnaba, M Levrero, G Ruberti, et al.
Liver|February 1, 1986
Characterization of effector cells in lymphocytotoxicity to autologous hepatocytes in HBsAg-positive and autoimmune chronic active hepatitis (CAH)V Barnaba, M Levrero, A Franco, et al.
The Journal of Biological Chemistry|December 23, 1999
Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptorG Papoff, P Hausler, A Eramo, et al.
The EMBO Journal|December 1, 1995
Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signalM G Cifone, P Roncaioli, R De Maria, et al.
Human Immunology|May 1, 1991
Molecular analysis of the role of the HLA class II genes DRB1, DQA1, DQB1, and DPB1 in susceptibility to Lyme arthritisG Ruberti, A B Begovich, A C Steere, et al.
Cell Death and Differentiation|April 14, 1999
The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosisM Tolomeo, L Dusonchet, M Meli, et al.
Journal of Hepatology|January 1, 1986
Effect of 28 consecutive days lymphoblastoid interferon (alpha-IFN) administration on hepatitis B virus related chronic liver diseaseA Franco, V Barnaba, M Levrero, et al.
The Journal of Experimental Medicine|January 1, 1992
Presentation of antigen by mixed isotype class II molecules in normal H-2d miceG Ruberti, K S Sellins, C M Hill, et al.
Pageof 3